Poxvirus vectors as HIV/AIDS vaccines in humans

References

• Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643 - 56; http://dx.doi.org/10.1016/S0140-6736(07)60312-2; PMID: 17321310
   PubMed Web of Science ®Google Scholar
• Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al, CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168 - 74; http://dx.doi.org/10.1126/science.1193748; PMID: 20643915
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654 - 65; http://dx.doi.org/10.1086/428404; PMID: 15688278
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191:666 - 77; http://dx.doi.org/10.1086/428405; PMID: 15688279
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al, Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881 - 93; http://dx.doi.org/10.1016/S0140-6736(08)61591-3; PMID: 19012954
   PubMed Web of Science ®Google Scholar
• McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al, Step Study Protocol Team. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894 - 905; http://dx.doi.org/10.1016/S0140-6736(08)61592-5; PMID: 19012957
   PubMed Web of Science ®Google Scholar
• Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010; 5:357 - 61; http://dx.doi.org/10.1097/COH.0b013e32833d2d2b; PMID: 20978374
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al, MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209 - 20; http://dx.doi.org/10.1056/NEJMoa0908492; PMID: 19843557
   PubMed Web of Science ®Google Scholar
• McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010; 33:542 - 54; http://dx.doi.org/10.1016/j.immuni.2010.09.011; PMID: 21029964
   PubMed Web of Science ®Google Scholar
• Paris R, Bejrachandra S, Thongcharoen P, Nitayaphan S, Pitisuttithum P, Sambor A, et al, Thai AIDS Vaccine Evaluation Group. HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E. Vaccine 2012; 30:832 - 6; http://dx.doi.org/10.1016/j.vaccine.2011.11.002; PMID: 22085554
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275 - 86; http://dx.doi.org/10.1056/NEJMoa1113425; PMID: 22475592
   PubMed Web of Science ®Google Scholar
• Kresge KJ. A Bangkok surprise. IAVI Rep 2011; 15:4 - 8; PMID: 22111192
   PubMedGoogle Scholar
• Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 1982; 79:7415 - 9; http://dx.doi.org/10.1073/pnas.79.23.7415; PMID: 6296831
   PubMed Web of Science ®Google Scholar
• Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A 1982; 79:4927 - 31; http://dx.doi.org/10.1073/pnas.79.16.4927; PMID: 6289324
   PubMed Web of Science ®Google Scholar
• Mackett M, Smith GL. Vaccinia virus expression vectors. J Gen Virol 1986; 67:2067 - 82; http://dx.doi.org/10.1099/0022-1317-67-10-2067; PMID: 3531399
   PubMed Web of Science ®Google Scholar
• Moss B. Vaccinia virus: a tool for research and vaccine development. Science 1991; 252:1662 - 7; http://dx.doi.org/10.1126/science.2047875; PMID: 2047875
   PubMed Web of Science ®Google Scholar
• Collier LH. The development of a stable smallpox vaccine. J Hyg (Lond) 1955; 53:76 - 101; http://dx.doi.org/10.1017/S002217240000053X; PMID: 14367805
   PubMedGoogle Scholar
• Pastoret PP, Vanderplasschen A. Poxviruses as vaccine vectors. Comp Immunol Microbiol Infect Dis 2003; 26:343 - 55; http://dx.doi.org/10.1016/S0147-9571(03)00019-5; PMID: 12818621
   PubMed Web of Science ®Google Scholar
• Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969; 281:1201 - 8; http://dx.doi.org/10.1056/NEJM196911272812201; PMID: 4186802
   PubMed Web of Science ®Google Scholar
• Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987; 316:673 - 6; http://dx.doi.org/10.1056/NEJM198703123161106; PMID: 3821799
   PubMed Web of Science ®Google Scholar
• Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 2003; 3:263 - 71; http://dx.doi.org/10.2174/1568005033481123; PMID: 14529359
   PubMedGoogle Scholar
• Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006; 344:230 - 9; http://dx.doi.org/10.1016/j.virol.2005.09.020; PMID: 16364753
   PubMed Web of Science ®Google Scholar
• Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccin 2009; 5:867 - 71; PMID: 19786840
   PubMed Web of Science ®Google Scholar
• Gómez CE, Nájera JL, Krupa M, Perdiguero B, Esteban M. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 2011; 11:189 - 217; http://dx.doi.org/10.2174/156652311795684731; PMID: 21453284
   PubMed Web of Science ®Google Scholar
• Pantaleo G, Esteban M, Jacobs B, Tartaglia J. Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS 2010; 5:391 - 6; http://dx.doi.org/10.1097/COH.0b013e32833d1e87; PMID: 20978379
   PubMed Web of Science ®Google Scholar
• Weli SC, Tryland M. Avipoxviruses: infection biology and their use as vaccine vectors. Virol J 2011; 8:49; http://dx.doi.org/10.1186/1743-422X-8-49; PMID: 21291547
   PubMed Web of Science ®Google Scholar
• Mayr A, Stickl H, Müller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author’s transl)]. Zentralbl Bakteriol B 1978; 167:375 - 90; PMID: 219640
   PubMedGoogle Scholar
• Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998; 244:365 - 96; http://dx.doi.org/10.1006/viro.1998.9123; PMID: 9601507
   PubMed Web of Science ®Google Scholar
• Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 1992; 89:10847 - 51; http://dx.doi.org/10.1073/pnas.89.22.10847; PMID: 1438287
   PubMed Web of Science ®Google Scholar
• Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998; 79:347 - 52; PMID: 9472619
   PubMed Web of Science ®Google Scholar
• Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006; 24:417 - 25; http://dx.doi.org/10.1016/j.vaccine.2005.08.041; PMID: 16176847
   PubMed Web of Science ®Google Scholar
• Guimarães-Walker A, Mackie N, McCormack S, Hanke T, Schmidt C, Gilmour J, et al, IAVI-006 Study Group. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 2008; 26:6671 - 7; http://dx.doi.org/10.1016/j.vaccine.2008.09.016; PMID: 18812202
   PubMed Web of Science ®Google Scholar
• Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, Nanvubya A, et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008; 26:2788 - 95; http://dx.doi.org/10.1016/j.vaccine.2008.02.071; PMID: 18440674
   PubMed Web of Science ®Google Scholar
• Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85:911 - 9; http://dx.doi.org/10.1099/vir.0.19701-0; PMID: 15039533
   PubMed Web of Science ®Google Scholar
• Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 2007; 25:2120 - 7; http://dx.doi.org/10.1016/j.vaccine.2006.11.016; PMID: 17250931
   PubMed Web of Science ®Google Scholar
• García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 2011; 29:8309 - 16; http://dx.doi.org/10.1016/j.vaccine.2011.08.098; PMID: 21907749
   PubMed Web of Science ®Google Scholar
• Gómez CE, Nájera JL, Perdiguero B, García-Arriaza J, Sorzano CO, Jiménez V, et al. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol 2011; 85:11468 - 78; http://dx.doi.org/10.1128/JVI.05165-11; PMID: 21865377
   PubMed Web of Science ®Google Scholar
• Aboud S, Nilsson C, Karlén K, Marovich M, Wahren B, Sandström E, et al. Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes. Clin Vaccine Immunol 2010; 17:1124 - 31; http://dx.doi.org/10.1128/CVI.00008-10; PMID: 20463104
   PubMed Web of Science ®Google Scholar
• Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 2011; 29:8417 - 28; http://dx.doi.org/10.1016/j.vaccine.2011.08.001; PMID: 21864626
   PubMed Web of Science ®Google Scholar
• Sandström E, Nilsson C, Hejdeman B, Bråve A, Bratt G, Robb M, et al, HIV Immunogenicity Study 01/02 Team. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008; 198:1482 - 90; http://dx.doi.org/10.1086/592507; PMID: 18808335
   PubMed Web of Science ®Google Scholar
• Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, et al. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009; 27:4468 - 74; http://dx.doi.org/10.1016/j.vaccine.2009.05.018; PMID: 19450644
   PubMed Web of Science ®Google Scholar
• Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 2010; 5:e13983; http://dx.doi.org/10.1371/journal.pone.0013983; PMID: 21085591
   PubMed Web of Science ®Google Scholar
• Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, et al, National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011; 203:610 - 9; http://dx.doi.org/10.1093/infdis/jiq105; PMID: 21282192
   PubMed Web of Science ®Google Scholar
• Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, et al, NIAID HIV Vaccine Trials Network. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 2011; 29:1948 - 58; http://dx.doi.org/10.1016/j.vaccine.2010.12.104; PMID: 21216311
   PubMed Web of Science ®Google Scholar
• Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, et al. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B’/C candidate vaccine. PLoS One 2010; 5:e8816; http://dx.doi.org/10.1371/journal.pone.0008816; PMID: 20111599
   PubMed Web of Science ®Google Scholar
• Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 2006; 80:4717 - 28; http://dx.doi.org/10.1128/JVI.80.10.4717-4728.2006; PMID: 16641265
   PubMed Web of Science ®Google Scholar
• Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, et al. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses 2009; 25:1107 - 16; http://dx.doi.org/10.1089/aid.2009.0096; PMID: 19943789
   PubMed Web of Science ®Google Scholar
• Gorse GJ, Newman MJ, Decamp A, Hay CM, De Rosa SC, Noonan E, et al, the NIAID HIV Vaccine Trials Network. DNA and Modified Vaccinia Virus Ankara Vaccines Encoding Multiple Cytotoxic and Helper T-Lymphocyte Epitopes of Human Immunodeficiency Virus Type 1 (HIV-1) Are Safe but Weakly Immunogenic in HIV-1-Uninfected, Vaccinia Virus-Naive Adults. Clin Vaccine Immunol 2012; 19:649 - 58; http://dx.doi.org/10.1128/CVI.00038-12; PMID: 22398243
   PubMed Web of Science ®Google Scholar
• Tartaglia J, Cox WI, Taylor J, Perkus M, Riviere M, Meignier B, et al. Highly attenuated poxvirus vectors. AIDS Res Hum Retroviruses 1992; 8:1445 - 7; PMID: 1466978
   PubMed Web of Science ®Google Scholar
• Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008; 205:63 - 77; http://dx.doi.org/10.1084/jem.20071331; PMID: 18195071
   PubMed Web of Science ®Google Scholar
• McCormack S, Stöhr W, Barber T, Bart PA, Harari A, Moog C, et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008; 26:3162 - 74; http://dx.doi.org/10.1016/j.vaccine.2008.02.072; PMID: 18502003
   PubMed Web of Science ®Google Scholar
• Bart PA, Goodall R, Barber T, Harari A, Guimaraes-Walker A, Khonkarly M, et al, EuroVacc Consortium. EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 2008; 26:3153 - 61; http://dx.doi.org/10.1016/j.vaccine.2008.03.083; PMID: 18502002
   PubMed Web of Science ®Google Scholar
• Perreau M, Welles HC, Harari A, Hall O, Martin R, Maillard M, et al. DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa. J Virol 2011; 85:9854 - 62; http://dx.doi.org/10.1128/JVI.00788-11; PMID: 21775454
   PubMed Web of Science ®Google Scholar
• Levy Y, Ellefsen K, Stöehr W, Bart PA, Lelièvere JD, Launay O, et al. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens requires 3 DNA injections. Results of the randomized multicentre EV03/ANRS Vac20 Phase I/II Trial. 2010:CROI.
   Google Scholar
• Tulman ER, Afonso CL, Lu Z, Zsak L, Kutish GF, Rock DL. The genome of canarypox virus. J Virol 2004; 78:353 - 66; http://dx.doi.org/10.1128/JVI.78.1.353-366.2004; PMID: 14671117
   PubMed Web of Science ®Google Scholar
• Afonso CL, Tulman ER, Lu Z, Zsak L, Kutish GF, Rock DL. The genome of fowlpox virus. J Virol 2000; 74:3815 - 31; http://dx.doi.org/10.1128/JVI.74.8.3815-3831.2000; PMID: 10729156
   PubMed Web of Science ®Google Scholar
• Sadasiv EC, Chang PW, Gulka G. Morphogenesis of canary poxvirus and its entrance into inclusion bodies. Am J Vet Res 1985; 46:529 - 35; PMID: 2986493
   PubMed Web of Science ®Google Scholar
• Taylor J, Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine 1988; 6:466 - 8; http://dx.doi.org/10.1016/0264-410X(88)90091-6; PMID: 2854335
   PubMed Web of Science ®Google Scholar
• Weli SC, Nilssen O, Traavik T. Avipoxvirus multiplication in a mammalian cell line. Virus Res 2005; 109:39 - 49; http://dx.doi.org/10.1016/j.virusres.2004.10.009; PMID: 15826911
   PubMed Web of Science ®Google Scholar
• Somogyi P, Frazier J, Skinner MA. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology 1993; 197:439 - 44; http://dx.doi.org/10.1006/viro.1993.1608; PMID: 8212580
   PubMed Web of Science ®Google Scholar
• Zanotto C, Pozzi E, Pacchioni S, Volonté L, De Giuli Morghen C, Radaelli A. Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and immunological comparison. Antiviral Res 2010; 88:53 - 63; http://dx.doi.org/10.1016/j.antiviral.2010.07.005; PMID: 20643163
   PubMed Web of Science ®Google Scholar
• Van Rompay KK, Abel K, Lawson JR, Singh RP, Schmidt KA, Evans T, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005; 38:124 - 34; http://dx.doi.org/10.1097/00126334-200502010-00002; PMID: 15671796
   PubMed Web of Science ®Google Scholar
• Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC, Miller NR, et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 2002; 76:292 - 302; http://dx.doi.org/10.1128/JVI.76.1.292-302.2002; PMID: 11739694
   PubMed Web of Science ®Google Scholar
• Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, et al. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 2006; 80:3732 - 42; http://dx.doi.org/10.1128/JVI.80.8.3732-3742.2006; PMID: 16571790
   PubMed Web of Science ®Google Scholar
• Andersson S, Mäkitalo B, Thorstensson R, Franchini G, Tartaglia J, Limbach K, et al. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis 1996; 174:977 - 85; http://dx.doi.org/10.1093/infdis/174.5.977; PMID: 8896498
   PubMed Web of Science ®Google Scholar
• Girard M, van der Ryst E, Barré-Sinoussi F, Nara P, Tartaglia J, Paoletti E, et al. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus. Virology 1997; 232:98 - 104; http://dx.doi.org/10.1006/viro.1997.8560; PMID: 9185593
   PubMed Web of Science ®Google Scholar
• Marovich MA. ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development. Expert Rev Vaccines 2004; 3:Suppl S99 - 104; http://dx.doi.org/10.1586/14760584.3.4.S99; PMID: 15285709
   PubMedGoogle Scholar
• Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 2004; 3:Suppl S75 - 88; http://dx.doi.org/10.1586/14760584.3.4.S75; PMID: 15285707
   PubMed Web of Science ®Google Scholar
• de Bruyn G, Rossini AJ, Chiu YL, Holman D, Elizaga ML, Frey SE, et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 2004; 22:704 - 13; PMID: 14741163
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Cadoz M, Meignier B, Méric C, Leroy O, Excler JL, et al. The safety and use of canarypox vectored vaccines. Dev Biol Stand 1995; 84:165 - 70; PMID: 7796950
   PubMedGoogle Scholar
• Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, et al, NIAID AIDS Vaccine Clinical Trials Network. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994; 272:475 - 80; http://dx.doi.org/10.1001/jama.1994.03520060075035; PMID: 7913731
   PubMed Web of Science ®Google Scholar
• Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K, et al, NIAID AIDS Vaccine Clinical Trials Network. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med 1991; 114:119 - 27; PMID: 1984386
   PubMed Web of Science ®Google Scholar
• Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, et al, The NIAID AIDS Vaccine Clinical Trials Network. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 1993; 167:533 - 7; http://dx.doi.org/10.1093/infdis/167.3.533; PMID: 8095059
   PubMed Web of Science ®Google Scholar
• Kovacs JA, Vasudevachari MB, Easter M, Davey RT, Falloon J, Polis MA, et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160. J Clin Invest 1993; 92:919 - 28; http://dx.doi.org/10.1172/JCI116667; PMID: 7688766
   PubMed Web of Science ®Google Scholar
• Belshe RB, Clements ML, Dolin R, Graham BS, McElrath J, Gorse GJ, et al, National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis 1993; 168:1387 - 95; http://dx.doi.org/10.1093/infdis/168.6.1387; PMID: 8245523
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Graham BS, Zhou J, Zhou J, Bucco RA, Schwartz DH, et al, NIH-NIAID AIDS Vaccine Clinical Trials Network. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. J Clin Invest 1993; 92:840 - 7; http://dx.doi.org/10.1172/JCI116658; PMID: 8349820
   PubMed Web of Science ®Google Scholar
• Schwartz DH, Gorse G, Clements ML, Belshe R, Izu A, Duliege AM, et al. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet 1993; 342:69 - 73; http://dx.doi.org/10.1016/0140-6736(93)91283-R; PMID: 8100910
   PubMed Web of Science ®Google Scholar
• Kahn JO, Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman RL, et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis 1994; 170:1288 - 91; http://dx.doi.org/10.1093/infdis/170.5.1288; PMID: 7963729
   PubMed Web of Science ®Google Scholar
• Pialoux G, Excler JL, Rivière Y, Gonzalez-Canali G, Feuillie V, Coulaud P, et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l’Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses 1995; 11:373 - 81; http://dx.doi.org/10.1089/aid.1995.11.373; PMID: 7598771
   PubMed Web of Science ®Google Scholar
• Egan MA, Pavlat WA, Tartaglia J, Paoletti E, Weinhold KJ, Clements ML, et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis 1995; 171:1623 - 7; http://dx.doi.org/10.1093/infdis/171.6.1623; PMID: 7769304
   PubMed Web of Science ®Google Scholar
• Fleury B, Janvier G, Pialoux G, Buseyne F, Robertson MN, Tartaglia J, et al. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996; 174:734 - 8; http://dx.doi.org/10.1093/infdis/174.4.734; PMID: 8843210
   PubMed Web of Science ®Google Scholar
• Tartaglia J, Excler JL, El Habib R, Limbach K, Meignier B, Plotkin S, et al. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses 1998; 14:Suppl 3 S291 - 8; PMID: 9814957
   PubMedGoogle Scholar
• Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, et al, NIAID AIDS Vaccine Evaluation Group. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998; 12:2407 - 15; http://dx.doi.org/10.1097/00002030-199818000-00009; PMID: 9875578
   PubMed Web of Science ®Google Scholar
• Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, et al, National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007; 44:203 - 12; http://dx.doi.org/10.1097/01.qai.0000248356.48501.ff; PMID: 17106277
   PubMed Web of Science ®Google Scholar
• Team TAVEGP, AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis 2001; 183:563 - 70; http://dx.doi.org/10.1086/318523; PMID: 11170981
   PubMed Web of Science ®Google Scholar
• Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, et al, The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996; 173:340 - 8; http://dx.doi.org/10.1093/infdis/173.2.340; PMID: 8568294
   PubMed Web of Science ®Google Scholar
• Verrier F, Burda S, Belshe R, Duliege AM, Excler JL, Klein M, et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. J Virol 2000; 74:10025 - 33; http://dx.doi.org/10.1128/JVI.74.21.10025-10033.2000; PMID: 11024131
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, Xu S, Burda S, Duliege AM, Excler JL, Clements-Mann ML. Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines. J Infect Dis 1998; 178:1502 - 6; http://dx.doi.org/10.1086/314452; PMID: 9780275
   PubMed Web of Science ®Google Scholar
• Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P, et al, Thai AIDS Vaccine Evaluation Group. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004; 190:702 - 6; http://dx.doi.org/10.1086/422258; PMID: 15272397
   PubMed Web of Science ®Google Scholar
• Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, et al, for the Thai AIDS Vaccine Evaluation Group. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007; 46:48 - 55; PMID: 17909315
   PubMed Web of Science ®Google Scholar
• Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, et al, NIAID AIDS Vaccine Evaluation Group. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 1998; 177:1230 - 46; http://dx.doi.org/10.1086/515288; PMID: 9593008
   PubMed Web of Science ®Google Scholar
• Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 1997; 94:1396 - 401; http://dx.doi.org/10.1073/pnas.94.4.1396; PMID: 9037064
   PubMed Web of Science ®Google Scholar
• Salmon-Céron D, Excler JL, Finkielsztejn L, Autran B, Gluckman JC, Sicard D, et al. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L’Agence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses 1999; 15:633 - 45; http://dx.doi.org/10.1089/088922299310935; PMID: 10331442
   PubMed Web of Science ®Google Scholar
• Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, et al, National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (HIVNET). Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001; 183:1343 - 52; http://dx.doi.org/10.1086/319863; PMID: 11294665
   PubMed Web of Science ®Google Scholar
• Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, et al, AIDS Vaccine Evaluation Group. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002; 29:254 - 61; PMID: 11873074
   PubMed Web of Science ®Google Scholar
• Cao H, Kaleebu P, Hom D, Flores J, Agrawal D, Jones N, et al, HIV Network for Prevention Trials. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infect Dis 2003; 187:887 - 95; http://dx.doi.org/10.1086/368020; PMID: 12660934
   PubMed Web of Science ®Google Scholar
• Eller MA, Slike BM, Cox JH, Lesho E, Wang Z, Currier JR, et al. A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells. PLoS One 2011; 6:e24254; http://dx.doi.org/10.1371/journal.pone.0024254; PMID: 21949699
   PubMedGoogle Scholar
• Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, et al, NIAID HIV Vaccine Trials Network. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 2005; 192:1249 - 59; http://dx.doi.org/10.1086/432915; PMID: 16136469
   PubMed Web of Science ®Google Scholar
• Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, et al, 026 Protocol Team and the NIAID HIV Vaccine Trials Network. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr 2007; 46:222 - 30; http://dx.doi.org/10.1097/QAI.0b013e318149297d; PMID: 17693888
   PubMed Web of Science ®Google Scholar
• Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999; 180:290 - 8; http://dx.doi.org/10.1086/314895; PMID: 10395842
   PubMed Web of Science ®Google Scholar
• Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, et al, Thai AIDS Vaccine Evaluation Group, Thailand. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005; 23:2522 - 9; http://dx.doi.org/10.1016/j.vaccine.2004.10.028; PMID: 15752839
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One 2011; 6:e27837; http://dx.doi.org/10.1371/journal.pone.0027837; PMID: 22205930
   PubMed Web of Science ®Google Scholar
• Coupar BE, Purcell DF, Thomson SA, Ramshaw IA, Kent SJ, Boyle DB. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine 2006; 24:1378 - 88; http://dx.doi.org/10.1016/j.vaccine.2005.09.044; PMID: 16257479
   PubMed Web of Science ®Google Scholar
• Dale CJ, De Rose R, Wilson KM, Croom HA, Thomson S, Coupar BE, et al, Australian Thai HIV Vaccine Consortium. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12. Vaccine 2004; 23:188 - 97; http://dx.doi.org/10.1016/j.vaccine.2004.05.024; PMID: 15531036
   PubMed Web of Science ®Google Scholar
• De Rose R, Batten CJ, Smith MZ, Fernandez CS, Peut V, Thomson S, et al. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol 2007; 81:292 - 300; http://dx.doi.org/10.1128/JVI.01727-06; PMID: 17050602
   PubMed Web of Science ®Google Scholar
• De Rose R, Chea S, Dale CJ, Reece J, Fernandez CS, Wilson KM, et al. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine 2005; 23:1949 - 56; http://dx.doi.org/10.1016/j.vaccine.2004.10.012; PMID: 15734067
   PubMed Web of Science ®Google Scholar
• Radaelli A, Bonduelle O, Beggio P, Mahe B, Pozzi E, Elli V, et al. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. Vaccine 2007; 25:2128 - 38; http://dx.doi.org/10.1016/j.vaccine.2006.11.009; PMID: 17241705
   PubMed Web of Science ®Google Scholar
• Radaelli A, Zanotto C, Perletti G, Elli V, Vicenzi E, Poli G, et al. Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV. Vaccine 2003; 21:2052 - 64; http://dx.doi.org/10.1016/S0264-410X(02)00773-9; PMID: 12706695
   PubMed Web of Science ®Google Scholar
• Santra S, Sun Y, Parvani JG, Philippon V, Wyand MS, Manson K, et al. Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. J Virol 2007; 81:8563 - 70; http://dx.doi.org/10.1128/JVI.00744-07; PMID: 17553898
   PubMed Web of Science ®Google Scholar
• Kelleher AD, Puls RL, Bebbington M, Boyle D, Ffrench R, Kent SJ, et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006; 20:294 - 7; http://dx.doi.org/10.1097/01.aids.0000199819.40079.e9; PMID: 16511428
   PubMed Web of Science ®Google Scholar
• Hemachandra A, Puls RL, Sirivichayakul S, Kerr S, Thantiworasit P, Ubolyam S, et al. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hum Vaccin 2010; 6:835 - 40; http://dx.doi.org/10.4161/hv.6.10.12635; PMID: 20864808
   PubMed Web of Science ®Google Scholar
• Combadiere B, Boissonnas A, Carcelain G, Lefranc E, Samri A, Bricaire F, et al. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 2004; 199:1585 - 93; http://dx.doi.org/10.1084/jem.20032083; PMID: 15184506
   PubMed Web of Science ®Google Scholar
• Kannanganat S, Nigam P, Velu V, Earl PL, Lai L, Chennareddi L, et al. Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. J Immunol 2010; 185:7262 - 73; http://dx.doi.org/10.4049/jimmunol.1000751; PMID: 21076059
   PubMed Web of Science ®Google Scholar
• Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 2003; 3:36 - 50; http://dx.doi.org/10.1038/nri980; PMID: 12511874
   PubMed Web of Science ®Google Scholar
• Perdiguero B, Esteban M. The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 2009; 29:581 - 98; http://dx.doi.org/10.1089/jir.2009.0073; PMID: 19708815
   PubMed Web of Science ®Google Scholar
• García-Arriaza J, Nájera JL, Gómez CE, Sorzano CO, Esteban M. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One 2010; 5:e12395; http://dx.doi.org/10.1371/journal.pone.0012395; PMID: 20811493
   PubMed Web of Science ®Google Scholar
• García-Arriaza J, Nájera JL, Gómez CE, Tewabe N, Sorzano CO, Calandra T, et al. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One 2011; 6:e24244; http://dx.doi.org/10.1371/journal.pone.0024244; PMID: 21909386
   PubMed Web of Science ®Google Scholar
• Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, Holechek S, et al. Improved NYVAC-based vaccine vectors. PLoS One 2011; 6:e25674; http://dx.doi.org/10.1371/journal.pone.0025674; PMID: 22096477
   PubMed Web of Science ®Google Scholar
• Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, Duhen T, et al. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One 2011; 6:e16819; http://dx.doi.org/10.1371/journal.pone.0016819; PMID: 21347234
   PubMed Web of Science ®Google Scholar
• Falivene J, Del Médico Zajac MP, Pascutti MF, Rodríguez AM, Maeto C, Perdiguero B, et al. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One 2012; 7:e32220; http://dx.doi.org/10.1371/journal.pone.0032220; PMID: 22384183
   PubMed Web of Science ®Google Scholar
• Gómez CE, Perdiguero B, Nájera JL, Sorzano CO, Jiménez V, González-Sanz R, et al. Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 2012; 86:5026 - 38; http://dx.doi.org/10.1128/JVI.06684-11; PMID: 22419805
   PubMed Web of Science ®Google Scholar